Home > Insider Trading > Filing (0001209191-20-064497)

Filing Details

Accession Number:: 0001209191-20-064497
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-12-18 18:26:35
Reporting Period:: 2020-12-07

Accepted Time:: 2020-12-18 18:26:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
879407	Arrowhead Pharmaceuticals Inc.	ARWR	Pharmaceutical Preparations (2834)	460408024

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1156207	B Douglas Given	177 E. Colorado Blvd Suite 700 Pasadena CA 91105		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-12-07	31,000	$0.00	123,813	No	5	G	Direct
Common Stock	Acquisiton	2020-12-07	15,500	$0.00	15,500	No	5	G	Indirect	By Trust
Common Stock	Acquisiton	2020-12-07	15,500	$0.00	15,500	No	5	G	Indirect	By Trust
Common Stock	Disposition	2020-12-17	9,075	$79.30	114,738	No	4	S	Direct
Common Stock	Disposition	2020-12-17	500	$79.59	15,000	No	4	S	Indirect	By Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	G	Direct
No	5	G	Indirect	By Trust
No	5	G	Indirect	By Trust
No	4	S	Direct
No	4	S	Indirect	By Trust

Footnotes

Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
Represents securities owned directly by Anne Given Trust ("AG Trust"). Mr. Given, as co-trustee of AG Trust, may be deemed to beneficially own the securities owned directly by AG Trust.
Represents securities owned directly by Katherine Given Ligtenberg Trust ("KGL Trust"). Mr. Given, as co-trustee of KGL Trust, may be deemed to beneficially own the securities owned directly by KGL Trust.
The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.75 to $79.65, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.57 to $79.63, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.